申请人:TOYO SUISAN KAISHA, LTD.
公开号:US20020173471A1
公开(公告)日:2002-11-21
An anticancer drug includes a compound represented by Formula (1):
1
where R
101
represents an acyl moiety of a saturated higher fatty acid, and R
102
represents a hydrogen atom or an acyl moiety of a saturated higher fatty acid, and/or a pharmaceutically acceptable salt thereof.
抗癌药物包括由式(1)代表的化合物:
1
其中 R
101
代表饱和高级脂肪酸的酰基,R
102
代表氢原子或饱和高级脂肪酸的酰基,和/或其药学上可接受的盐。